Octreotide in the therapy of recurrent medulloblastomas
BACKGROUND: Recurrence of medulloblastoma appears after 30% to 40% of the surgeries. Different from primary medulloblastoma, in which five-year survival rate is 50%, the survival time of relapses much shorter and only 20% of the patients manage to survive a year. There is a logical need for addition...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institute of Oncology, Sremska Kamenica, Serbia
2006-01-01
|
| Series: | Archive of Oncology |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0354-7310/2006/0354-73100602026S.pdf |